To take full advantage of this site, please enable your browser's JavaScript feature.
Learn how
AVISCERA BIOSCIENCE
CHECKOUT (
0
)
My Account
Log In
Contact Us
High Sensitivity ELISA
Receptor Assay
Research Area
New Products
ELISA
Recombinant
Antibody
More Information
Home
>
Recombinant
>
Biotinylated
>
S1 Spike Protein Microplate
Our Price:
$
360.00
Product Code:
PL00706-02
Qty:
Description
Technical Specs
Feature:
High Purity Spike S1 His Tag expressed from HEK293 cells
S1 Spike Protein His Tag Specifically biding to rh ACE2 Fc Fusion (HEK293).
That was tested by Human Soluble ACE2 Fc Biotinylated.
That was tested by Humanized monoclonal anti S1-RBD IgG
Size: 96 wells
Data Sheet:
PDF
FOR RESEARCH USE ONLY.
not to be used for human and animals.
not to be used as a clinical diagnostic test.
Features
Feature:
High Purity Spike S1 His Tag expressed from HEK293 cells
S1 Spike Protein His Tag Specifically biding to rh ACE2 Fc Fusion (HEK293).
That was tested by Human Soluble ACE2 Fc Biotinylated.
That was tested by Humanized monoclonal anti S1-RBD IgG
Size: 96 wells
FOR RESEARCH USE ONLY.
not to be used for human and animals.
not to be used as a clinical diagnostic test.
Accessories
Angiotensin-Converting Enzyme 2 (ACE2) (Human) ELISA Kit
Our Price:
$490.00
Add
Soluble TLT-1/TREML1 (Trem-like Transcript 1 ) (Human) Biotinylated
Stanniocalcin-1 (STC-1) (Human) Recombinant Biotinylated
S1 Spike Protein (SARS-CoV-2) Omicron Variant (HEK293) Biotinylated
S1 Spike Protein His Tag (HEK293) Biotinylated
Our Price:
$590.00
Add
Our Price:
$450.00
Add
Our Price:
$369.00
Add
Our Price:
$860.00
Add
IL-1F7 /IL-37 (Human) Recombinant Biotinylated
TIMP 2 (Human) (HEK293)
RBD-S1 Spike Protein (SARS-CoV-2) His Tag (HEK293)
Human TIM-3 His Tag (HEK293) Biotinylated
Our Price:
$490.00
Add
Our Price:
$179.00
Add
Add
Our Price:
$590.00
Add
Browse for more products in the same category as this item:
Recombinant
>
Biotinylated
Research Area
>
Inflammation
Copyright ©
2016
Aviscera Bioscience, Inc.. All Rights Reserved.
Built with
Volusion
.
